AB0340 Tapering Strategy in Patients with Rheumatoid Arthritis Receiving Tocilizumab

BackgroundClinical trials have demonstrated the efficacy of Tocilizumab (TCZ) for patients with rheumatoid arthritis (RA). Several studies have demonstrated that dose tapering of TNF-inhibitors is a feasible therapeutic option in rheumatic patients with low disease activity (LDA). Nevertheless, few reports analyse the effectiveness of dose-tapering of TCZ.ObjectivesTo evaluate the clinical outcome and incidence of flares in patients with RA in remission or LDA under a tapering strategy with TCZ and to analyse the influence of the tapering on serum drug levels.MethodsOf a cohort of 34 adult patients with RA under therapy with TCZ, 13 patients with sustained LDA or remission (DAS 28-ESR